Summary
Bristol-Myers Squibb (BMY) filed an 8-K on March 8, 2019, to provide crucial financial information regarding its previously announced proposed acquisition of Celgene Corporation. This filing includes the audited consolidated financial statements of Celgene for the years ended December 31, 2018, 2017, and 2016, along with the independent auditor's reports. Additionally, BMY has furnished unaudited pro forma condensed combined financial information, presenting a hypothetical view of the combined company's financial position and earnings as of December 31, 2018. These financial disclosures are essential for investors to assess the potential financial impact and to conduct their own due diligence on the proposed transaction. The pro forma information, while illustrative, offers insight into how the combined entity might look financially. Investors are strongly advised to refer to the definitive joint proxy statement/prospectus filed with the SEC for a comprehensive understanding of the transaction, its risks, and related details.
Key Highlights
- 1BMY is providing audited financial statements for Celgene as of December 31, 2018, and for the preceding two years, along with auditor reports.
- 2Unaudited pro forma condensed combined financial statements are included, illustrating the potential financial impact of the Celgene acquisition on BMY.
- 3The pro forma information is presented for informational purposes and does not represent actual future results of the combined company.
- 4The filing references a definitive joint proxy statement/prospectus filed earlier, urging investors to read it for important details about the transaction.
- 5Information regarding potential participants in the solicitation of proxies for the transaction is also provided.
- 6BMY includes a comprehensive cautionary statement regarding forward-looking statements, outlining significant risks and uncertainties associated with the proposed acquisition and future operations.